How can complex clinical trials be made more "user-friendly" for participants and more "efficient" for managers? With just a few taps, participants can now easily manage visit schedules, reimbursement progress, and medication services—no longer a mere concept. Recently, YIDU TECH (02158) and Peking University Cancer Hospital jointly launched the mobile version of their Clinical Trial Management System (CTMS), the "Beijing Cancer Hospital Clinical Trials" mini-program. This innovation not only embodies a "patient-centric" approach but also signifies a comprehensive upgrade in participant experience, data security, and operational efficiency.
**Three Key Upgrades: Simplified and Secure Participation** The newly launched CTMS mini-program prioritizes participant experience, shifting from a "management-focused" to a "service-oriented" model. Deeply integrated into the WeChat ecosystem, it offers multiple conveniences:
- **Easier Access**: Participants no longer need to download separate apps. Through the WeChat mini-program, they can check trial updates—visit schedules, locations, and required tests—in real time, track reimbursement status, and receive smart reminders. The mini-program also seamlessly connects with the hospital’s DTP (Direct-to-Patient) drug delivery system, enabling participants to access trial-related medications through a single portal, significantly lowering barriers to participation.
- **Enhanced Security**: Critical communications are conducted via official enterprise WeChat channels, while medical reports and trial protocols are encrypted via the CTMS platform, ensuring data security and minimizing risks from unofficial channels.
- **Seamless Continuity**: Leveraging enterprise WeChat features, when CRC (Clinical Research Coordinator) personnel change, previous communication records and project details are seamlessly transferred, eliminating redundant interactions and miscommunication. This ensures a smoother trial process, reducing participant burden.
These participant-centric improvements mark a successful expansion of clinical trial digitization from internal process management to external service optimization.
**Boosted Efficiency: CRC Workflow Optimization** The mini-program significantly enhances CRC productivity by breaking office-bound limitations. Tasks from PCs can now be synced to mobile devices, enabling on-the-go management. Core functions—such as adding participant details or updating trial status—are mobile-accessible, offering greater flexibility. Future updates will introduce remote e-consent and mobile-based AE (Adverse Event) assessment, further streamlining workflows.
**Proven Results: Accelerated Trial Initiation** Since adopting YIDU TECH’s CTMS in 2019, Peking University Cancer Hospital has advanced its "internet + clinical trial management" ecosystem. Their collaboration spans data governance and clinical research, including: - A medical data intelligence platform powering research insights. - Disease-specific databases (e.g., gastric cancer) standardizing treatment protocols. - An MDT platform and research ward system enhancing multidisciplinary collaboration.
As a GCP-compliant, end-to-end digital management solution, CTMS has cut the hospital’s average trial initiation time, outperforming industry benchmarks. The mobile extension further elevates both management efficiency and patient experience.
**Scalable Impact: Nationwide Adoption** Validated through this partnership, YIDU TECH’s CTMS now supports 60+ top-tier hospitals across China. Recognized as a key innovation at the 2025 Service Trade Fair, the system’s reliability and versatility facilitate complex trials. Beyond institutional management, CTMS integrates into the entire drug R&D chain—from discovery to approval—driving intelligent transformation and efficiency gains.
Moving forward, YIDU TECH will continue leveraging its expertise in medical AI to benefit more institutions, researchers, and participants, accelerating the delivery of safe, effective therapies to patients.
Comments